Drug Profile
Influenza virus liposome vaccine intranasal - Berna Biotech/Sanofi
Latest Information Update: 04 Apr 2022
Price :
$50
*
At a glance
- Originator Berna Biotech; sanofi pasteur
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 19 Jan 2005 Aventis Pasteur is now called sanofi pasteur
- 31 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 31 Oct 2002 Phase-I/II clinical trials in Influenza virus infections in Switzerland (Intranasal)